FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease
Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
